In CRC, metabolic reprogramming exhibits significant stage-dependent dynamics: early-stage tumors primarily activate glycolysis (15), while in advanced stages, tumors display various metabolic abnormalities, with lipid metabolism disorders (such as overexpression of fatty acid synthase, FASN) becoming increasingly prominent (16, 17). This evidence concerns the gene FASN and colorectal carcinoma.